JP7418324B2 - Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー - Google Patents

Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー Download PDF

Info

Publication number
JP7418324B2
JP7418324B2 JP2020517797A JP2020517797A JP7418324B2 JP 7418324 B2 JP7418324 B2 JP 7418324B2 JP 2020517797 A JP2020517797 A JP 2020517797A JP 2020517797 A JP2020517797 A JP 2020517797A JP 7418324 B2 JP7418324 B2 JP 7418324B2
Authority
JP
Japan
Prior art keywords
fgf
subject
treatment
compound
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535423A5 (https=
JP2020535423A (ja
Inventor
ハー．ラーデル クリストフ
ゲーリング ハンス
バイ－イェンスン アネ－クリスティーネ
カースデール モーデン
クビスト ピア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2020535423A publication Critical patent/JP2020535423A/ja
Publication of JP2020535423A5 publication Critical patent/JP2020535423A5/ja
Application granted granted Critical
Publication of JP7418324B2 publication Critical patent/JP7418324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020517797A 2017-09-29 2018-09-28 Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー Active JP7418324B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194169 2017-09-29
EP17194169.3 2017-09-29
EP18169317 2018-04-25
EP18169317.7 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND

Publications (3)

Publication Number Publication Date
JP2020535423A JP2020535423A (ja) 2020-12-03
JP2020535423A5 JP2020535423A5 (https=) 2021-11-04
JP7418324B2 true JP7418324B2 (ja) 2024-01-19

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517797A Active JP7418324B2 (ja) 2017-09-29 2018-09-28 Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー

Country Status (16)

Country Link
US (2) US11467169B2 (https=)
EP (1) EP3688468B1 (https=)
JP (1) JP7418324B2 (https=)
CN (1) CN111164429B (https=)
AU (1) AU2018343980B2 (https=)
CA (1) CA3075713A1 (https=)
DK (1) DK3688468T3 (https=)
ES (1) ES2918249T3 (https=)
HR (1) HRP20220737T1 (https=)
HU (1) HUE058848T2 (https=)
IL (1) IL273574B2 (https=)
LT (1) LT3688468T (https=)
PL (1) PL3688468T3 (https=)
RS (1) RS63292B1 (https=)
SI (1) SI3688468T1 (https=)
WO (1) WO2019063756A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501531A (ja) 2006-08-25 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
JP2015533078A (ja) 2012-08-06 2015-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー
JP2016540761A (ja) 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339002A1 (en) 1996-10-16 2011-06-29 ZymoGenetics, Inc. Fibroblast growth factor homologs
ES2493840T3 (es) 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
AU2003287697A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス， インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AU2013301607B2 (en) 2012-08-06 2018-10-18 Merck Patent Gmbh Prognosis biomarkers in cartilage disorders
KR102622290B1 (ko) 2013-12-24 2024-01-05 아레스 트레이딩 에스.아. 크실로글루칸 겔 중의 fgf-18 제형물
ES2806026T3 (es) 2013-12-24 2021-02-16 Ares Trading Sa Formulación de FGF-18 en hidrogeles de alginato/colágeno
HUE040350T2 (hu) * 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８を含むインプラント
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501531A (ja) 2006-08-25 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
JP2015533078A (ja) 2012-08-06 2015-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー
JP2016540761A (ja) 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIEBUHR A. S. et al.，Identification and characterization of osteoarthritis patients with inflammation derived tissue turnover，Osteoarthritis and Cartilage，2014年01月，Vol.22, No.1，pp.44-50
SIEBUHR A. S. et al.，Serological identification of fast progressors of structural damage with rheumatoid arthritis，Arthritis Research & Therapy，2013年08月14日，Vol.15, No.4，R86

Also Published As

Publication number Publication date
RS63292B1 (sr) 2022-06-30
HRP20220737T1 (hr) 2022-09-02
IL273574B1 (en) 2024-09-01
AU2018343980A1 (en) 2020-04-02
CN111164429B (zh) 2024-08-09
AU2018343980B2 (en) 2025-04-10
ES2918249T3 (es) 2022-07-14
EP3688468B1 (en) 2022-03-16
LT3688468T (lt) 2022-06-27
US12332250B2 (en) 2025-06-17
US20230258659A1 (en) 2023-08-17
PL3688468T3 (pl) 2022-07-18
US11467169B2 (en) 2022-10-11
IL273574B2 (en) 2025-01-01
SI3688468T1 (sl) 2022-08-31
WO2019063756A1 (en) 2019-04-04
IL273574A (en) 2020-05-31
CA3075713A1 (en) 2019-04-04
EP3688468A1 (en) 2020-08-05
CN111164429A (zh) 2020-05-15
DK3688468T3 (da) 2022-06-20
JP2020535423A (ja) 2020-12-03
HUE058848T2 (hu) 2022-09-28
US20210231680A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
JP7568614B2 (ja) 変形性関節症の治療のための富化戦略において有用なマーカー
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240109

R150 Certificate of patent or registration of utility model

Ref document number: 7418324

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150